"Betak": instructions for use, analogues and reviews

Beta1-adrenergic blocking agents are used to eliminate high blood pressure and various cardiac diseases. One of such medicines is the preparation "Betak". Instructions for use describe it as a medicine that displays cardioselective, antihypertensive and sympathomimetic effects.

Characteristic total

This drug is considered a synthetic beta-1 adrenoblocker. Produced by the Cyprus plant "Medokeemi LTD" in tablet form with a white or almost white shell coating.

Medication "Betak" instructions for use description of the drug contains the following character: the shape of them rounded with biconvex surfaces, there is a dividing line in the form of risks. If you break any tablet, its internal contents will be white or almost white.

On the drug "Betak" instruction on the application of the description of consumer packaging presents as follows: one pack contains three blisters. Each tablet cell is packaged with 10 tablets each.

Composition

In the drug, the main role is played by the active ingredient betaxolol in the form of hydrochloride salt. The dosage of each tablet is 0.020 g.

On the "Betak" tool instructions for the use of the composition of inactive ingredients describes without specifying their quantity. Tablets are formed by sodium glycolate, starchy, sugar, milk, magnesium stearate, microcrystalline type cellulose, aerosil, titanium oxide, hydroxymethylpropylcellulose and polyethylene glycol 400.

Mechanism of action

On the drug "Betak" instructions for use confirms cardioselective beta1 -adrenoceptor activity without internal sympathomimetic influence. Tablets exhibit weak membrane-stabilizing efficacy.

Antihypertensive activity is caused by actions that reduce the minute volume of the heart muscle and reduce sympathetic stimulation in the vessels around the periphery.

The selectivity of the effect of the drug on β ₁ -adrenoceptor formations can not be called unconditional, since high doses of betaxolol can affect β ₂ -adrenoactive receptor formations that are located in the bronchi and vessels.

The blocking effect of the drug, taking into account the pharmacodynamic characteristics, is associated with a decrease in heart rate at rest and during exercise. It occurs due to inhibition of β-adrenergic receptors in sinus nodes, which slows down their automatism.

Myocardial ejection in the active and passive state of the body, which is caused by competitive antagonism of catecholamines of nerve endings of peripheral and adrenergic type, also decreases.

The drug reduces systolic and diastolic pressure in the arteries in a calm state and under physical stress, removes the reflex of the orthostatic increase in the frequency of contractions of the heart. This effect of the drug reduces the load on the myocardium.

The beta-blocker has antihypertensive activity according to the following mechanism:

• Cardiac output decreases;
• Eliminates spasm in the arteries around the periphery due to a central action that limits the sympathetic impulse to the vascular walls during inhibition of renin activity.

Long-term prescribing does not reduce its hypotensive effect. If you take a single dose of betaxolol 0.005 or 0.04 g, then the pressure decrease will appear only after 3 or 4 hours.

On the "Betak" medication, the instructions for use indicate that administering a dosage of 0.005 g will cause an antihypertensive effect, the intensity of which will be half that of an entire tablet.

The maximum hypotensive activity of any concentration of betaxolol appears after 7-14 days.

Medicinal dosages of the drug do not cause a pronounced cardiodepressive effect, do not affect glucose metabolism, do not enhance the retention of sodium cations and fluid in tissues.

For what use

Preparation "Betak" instructions for the application of the testimony includes the following:

• High blood pressure;
• Ischemic myocardium disease, myocardial infarction;
• Hypertrophic cardiomyopathy.

The medication is prescribed when there are changes in the heart, which are expressed by the acceleration of the sinus rhythm, tachyarrhythmia of the supraventricular and ventricular nature, untimely depolarization of the myocardium, arrhythmia associated with prolapse in the mitral valve, excessive production of thyroid hormones.

How to use

On the drug "Betak" instructions for the application of the dose registers depending on the patient's condition. The entire daily dosage is drunk for one use. Food does not affect the absorption of the drug. The tablet should be washed down with clean water.

The increase in arterial pressure is treated with a daily initial dose of 0.005 to 0.010 g. After 7 or 14 days, if necessary, the amount of the drug is increased to 0.020 g.

Who should not apply

Not everyone is allowed to use the "Betak" tool instructions for use. Contraindications are associated with excessive sensitivity to the ingredients, as well as betaxolol hydrochloride.

It is not prescribed to patients who have chronic cardiac muscle failure, sinoatrial and atrioventricular blocking in the second and third degree, bradycardia, arterial hypotension, asthmatic bronchial seizures, spontaneous angina.

Medicines "Betak" tablets instructions for use also does not recommend drinking with cardiogenic type shock, angiotrophoneurosis of terminal vessels, an increase in myocardium muscle, asthenic ophthalmoplegia, endarteritis obliterating, emphysemic lesions of lung tissue, chronic obstructive bronchitis, diabetes mellitus.

Explicit changes in the activity of the kidneys and psoriasis rashes serve as a contraindication for therapy.

Adverse Reactions

To undesirable consequences of the means "Betak" instructions for use include delayed heartbeat, atrioventricular blockage, heart muscle insufficiency, orthostatic pressure reduction, weak blood circulation around the periphery, often cold hands and feet, paresthesia. So the work of the vascular system and heart is disrupted.

Bronchial spasm, rashes, urticaria, psoriasis, dryness of the mucous membrane of the eye may manifest adverse reactions of the respiratory and visual organs, skin.

The drug can provoke a drowsy, asthenic condition, depressive disorders, excessive fatigue, confused consciousness, hallucinations, dizziness and headache.

Undesirable processes in the digestive system are associated with nausea, vomiting, diarrhea, stool retention, cholestasis.

Other manifestations of the action of the drug may serve as a decrease in leukocyte and platelet blood cells, as well as a decrease in potency.

Features of treatment

The intake of any medication may be accompanied by certain nuances that depend on the pharmacotherapeutic group, the composition and dosage of the drug used.

Medicines "Betak" instruction on the use of special instructions leads to each non-standard case that requires attention.

So, in the very first stage of therapy, there may be an inadequate work of the cardiac muscle in people prone to this deviation.

Receiving tablets "Betak" masks the symptoms of hypoglycemia, the main of which is the violation of the rhythm of the heart. This knowledge should be taken into account for patients who have elevated levels of sugar. For them, regular monitoring of the concentration of glucose in the blood is necessary.

When using the "Betak" medication (tablets), the instructions for use recommend paying attention to monitoring the frequency of cardiac contractions. In the event of a bradycardic sinus rhythm disturbance, it is necessary to reduce the dosage or cancel treatment with this medication.

It requires careful use of the drug in patients who have pheochromocytoma formation.

Combination of the drug with the means by which inhalation anesthesia is carried out causes oppression of the myocardium muscle and lowering the arterial pressure. Nondepolarizing muscle relaxants show a longer action when exposed to Betak tablets.

If it is necessary to conduct planned surgical intervention, then the drug is canceled two days before the event, so that the tablets do not affect the general anesthesia.

Stop the treatment with the drug "Betak" instructions for use advises not immediately, but in stages, with a decrease in dosing for 7 or 14 days, in order to avoid the reaction of the body to the abolition of the medication. Every 3 days the amount of medicines is reduced by 0.005 g.

Tablets are not taken together with drugs that are related to moderates of monoamine oxidase enzyme.

The hypotensive effect of the drug reduces non-steroidal anti-inflammatory and estrogen medications that inhibit sodium ions and water, and also inhibit the synthesis of prostaglandin compounds inside the kidneys.

Simultaneous use of diltiazem, amiodarone and verapamil with Betak tablets leads to an increase in the inhibitory effect of betaxolol hydrochloride on myocardial muscle contractility and its conductivity.

The combination of the drug with cardiac glycoside drugs promotes the development of atrioventricular blockage.

Combination with other antihypertensive agents increases the hypotensive activity of the "Betak" tablets.

Cocaine reduces the therapeutic efficacy of betaxolol when administered concomitantly.

The combination of "Betak" tablets with adrenomimetics or xanthines causes a mutual weakening of their activity.

Phenothiazines and betaxolol hydrochloride interact with their content in the blood.

The drug "Betak" prevents the withdrawal of drugs containing lidocaine or theophylline.

Sulfasalazine increases the serum concentration of betaxolol hydrochloride.

There is no information on the use of the drug in children of childhood.

Care must be taken when using tablets for people driving a motor vehicle, as well as for pregnant and lactating women.

Such means

To beta1-adrenoblocker drugs, the "Betak" medication lists the instructions for use. Analogs also apply to this pharmacotherapeutic class. In their composition, the active ingredient is betaxolol hydrochloride.

The French analogue is the drug "Lokren", produced by the company "Sanofi Winthrop Industry" in the tablet form with a film white coating. Their shape is round with biconvex surfaces, on which the delicate and squashed designation "KE 20" is located.

There is one dose of 0.02 g of betaxolol hydrochloride. The auxiliary components of the drug include milk sugar, microcrystalline cellulose, sodium carboxymethyl starch type A, colloidal silicon dioxide, magnesium stearate.

In the film coating, you can find hypromellose, polyethylene glycol brand 400, titanium dioxide.

The drug is sold in cardboard packs with two blisters for 14 tablets.

The drug is used to eliminate high blood pressure, it is also combined with other drugs from hypertension.

The drug can be used for preventive measures to eliminate exacerbation of angina in a strained form.

The Russian equivalent is the drug Betaxolol, which is produced by the Moscow Endocrine Plant in the form of white tablets in a film shell. They have a circular shape with biconvex surfaces. The active ingredient is betaxolol hydrochloride in the amount of 0.020 g. The auxiliary components include milk sugar, sodium starch glycolate, aerosil dehydrated, magnesium stearate, microcrystalline cellulose. The film coating is formed by polyvinyl alcohol, titanium dioxide, talc, macrogol 3350, opadraem-2 white.

This drug is used systemically at high blood pressure.

There is still a drug "Betaxolol" in the form of eye drops that are applied topically in chronic open-angle glaucoma, with high intraocular pressure, with vision recovery after laser trabeculoplasty.

Patient's opinion

About the "Betak" tool instructions for use about adverse effects include in the "Adverse Reactions" section. These manifestations may not always occur when using a medication.

From many patients, you can hear positive feedback about Beta-adrenoblocker agent "Betak", which perfectly treats hypertension and angina. In general, tablets are taken together with other antihypertensive medications for complex therapy, which enhance their effectiveness.

After the course application pressure arterial comes to normal, which greatly improves the patient's well-being.

There are also reviews of the drug, which indicate the ineffectiveness of treatment with this drug.